Scholarlink

Background <p>Unmet medical needs persist across various therapeutic areas, underscoring the necessity for expanded treatment options. The United States Food and Drug Administration (USFDA) addresses these needs by approving efficacy supplements to New Drug Applications NDAs, allowing for the inclusion of new indications, dosing regimens, or patient populations for existing drugs. This mechanism supports the efficient utilization of prior clinical data to expedite access to vital therapies.</p> Objective <p>This study aims to examine trends in the USFDA’s NDA efficacy supplement approvals from 2019 to 2023, emphasizing their role in bridging therapeutic gaps.</p> Methods <p>Approval data was sourced from the USFDA database. The analysis focused on annual approval trends, dosage forms, key companies, and therapeutic areas.</p> Results <p>A total of 246 efficacy supplements were approved between 2019 and 2023. Oncology led with 38.4% of approvals, followed by cardiovascular (10.8%) and neurology (9%). Tablets (45.8%) and injections (25%) were the most common dosage forms. Leading companies included AstraZeneca, AbbVie, and Merck.</p> Conclusion <p>Efficacy supplements, submitted as NDA supplements, play an important role in expanding therapeutic options. While not all such approvals directly address unmet medical needs, they often contribute to incremental innovation and patient-centric regulatory pathways. The analysis highlights that approvals have remained relatively steady in recent years, underscoring the FDA’s ongoing role in facilitating adaptive regulatory mechanisms and supporting the availability of broader treatment choices.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exploring the Role and Trends of USFDA’s Efficacy Supplement Approvals for NDA in Fulfilling Unmet Medical Needs in Healthcare (2019–2023)

  • 期刊论文

  • 发表日期：

    2025年11月17日

查看全文
  • Sowndharya M,
  • Ramesh Joga,
  • Sravani Yerram,
  • Kajal Gandhi,
  • Sonali Waiker,
  • Gadekar Kailas Vijay,
  • Saurabh Srivastava

摘要

Background

Unmet medical needs persist across various therapeutic areas, underscoring the necessity for expanded treatment options. The United States Food and Drug Administration (USFDA) addresses these needs by approving efficacy supplements to New Drug Applications NDAs, allowing for the inclusion of new indications, dosing regimens, or patient populations for existing drugs. This mechanism supports the efficient utilization of prior clinical data to expedite access to vital therapies.

Objective

This study aims to examine trends in the USFDA’s NDA efficacy supplement approvals from 2019 to 2023, emphasizing their role in bridging therapeutic gaps.

Methods

Approval data was sourced from the USFDA database. The analysis focused on annual approval trends, dosage forms, key companies, and therapeutic areas.

Results

A total of 246 efficacy supplements were approved between 2019 and 2023. Oncology led with 38.4% of approvals, followed by cardiovascular (10.8%) and neurology (9%). Tablets (45.8%) and injections (25%) were the most common dosage forms. Leading companies included AstraZeneca, AbbVie, and Merck.

Conclusion

Efficacy supplements, submitted as NDA supplements, play an important role in expanding therapeutic options. While not all such approvals directly address unmet medical needs, they often contribute to incremental innovation and patient-centric regulatory pathways. The analysis highlights that approvals have remained relatively steady in recent years, underscoring the FDA’s ongoing role in facilitating adaptive regulatory mechanisms and supporting the availability of broader treatment choices.